Are Peptides Legal Now? What the October 2026 HHS Policy Means

Are Peptides Legal Now? What the October 2026 HHS Policy Means

Current regulatory status (updated October 29, 2026)

• What happened: HHS issued an interim enforcement discretion policy for six peptide bulk drug substances.
• Peptides covered: BPC-157, TB-500, KPV, MOTS-c, Epitalon, and Semax.
• Who it applies to: State-licensed 503A pharmacies, and licensed physicians compounding for individual patients.
• FDA-approved: No.
• Existing drug monograph: No.
• Federal Register: Filed October 28, 2026 and scheduled for publication October 30, 2026 (Docket No. HHS-OASH-2026-0496).
• Public comment: Open for two weeks after Federal Register publication.
• Can it change? Yes. HHS says it may reconsider the policy if safety signals or product-quality problems emerge.

What did HHS announce on October 28, 2026?

The U.S. Department of Health and Human Services (HHS) released an interim policy titled “Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances.” The policy says HHS does not intend to take enforcement action against a state-licensed pharmacy, or licensed physician that compounds a drug product using one of six listed peptide bulk drug substances, as long as the policy’s conditions are met.

This follows the July 23 and 24, 2026 meeting of the FDA’s Pharmacy Compounding Advisory Committee (PCAC), which recommended six of the seven peptides it reviewed for addition to the 503A Bulks List. The Advisory Committee’s votes were non-binding.

If you read our earlier regulatory status pages for BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax, this policy is the next step in that timeline.

Which six peptides does the policy cover?

The policy covers six named bulk drug substances. For each one, it names a specific chemical form and the routes of administration it covers.

Peptide	Form and routes named in the policy
BPC-157	Acetate: subcutaneous, intramuscular, oral, and topical dosage forms
TB-500	Acetate: subcutaneous or intramuscular injectable dosage forms
KPV	Acetate: topical and oral dosage forms
MOTS-c	Acetate: subcutaneous or intramuscular injectable dosage forms
Epitalon	Acetate: subcutaneous or intramuscular injectable dosage forms, dispensed in intermittent courses
Semax	Free base: intranasal

Emideltide (DSIP) is not covered. The Advisory Committee voted against recommending it in July.

Does this mean peptides are legal now?

Not in the way that many headlines suggest. The policy is enforcement discretion. It describes what HHS has decided not to pursue while FDA works through the formal rulemaking process. It does not approve any peptide, and it does not add any peptide to the 503A Bulks List.

Term	What it means	Where these six peptides stand
FDA approval	FDA has reviewed evidence of safety and effectiveness for a specific drug.	Not approved
503A Bulks List	A formal list of bulk drug substances that 503A pharmacies may use, added through notice-and-comment rulemaking.	Not on the list
Enforcement discretion	An agency decision not to take enforcement action while conditions are met. It can be changed or withdrawn.	Applies under this interim policy

The policy is intended to provide access to these peptides until FDA makes a final rulemaking decision. That rulemaking has no announced date.

What conditions must pharmacies meet?

The policy lists eight circumstances that must all be present for HHS’s enforcement discretion to apply:

1. Listed peptide. The bulk drug substance appears on the policy’s Interim Access List (Appendix A).
2. Defined identity and route. The substance matches the amino acid sequence, chemical structure, molecular weight, formula, and route of administration described in Appendix B.
3. Characterization. The substance comes from a facility registered with FDA and has a valid Certificate of Analysis with test results for identity, purity, potency, impurities and contaminants such as endotoxins, heavy metals, and microbial contamination. FDA has published very specific and strict criteria that must be met on chemical testing of these six peptides, all of which are outlined in Appendix B.
4. Original manufacturer. The original manufacturer is registered with FDA, follows Current Good Manufacturing Practice (cGMP), and has its facility location listed on the Certificate of Analysis. A repacker or reseller must have validated the manufacturer and its certificate.
5. Reporting. Compounders report products compounded, serious adverse events, and product quality issues to FDA (through MedWatch).
6. Labeling. Labeling includes the statement “This is a compounded drug product. Not for resale.” It must also explain how to report adverse events and quality problems.
7. Single active ingredient. The product contains only one active ingredient from the list.
8. Other requirements. The product is compounded in compliance with all other applicable requirements, including sanitary conditions and the patient-specific prescription requirement of section 503A.

What does the policy not change?

Several things stay the same.

It is not FDA approval. HHS states that the policy does not approve any of the six peptides or any compounded drug made from them. Compounded drugs are exempt from FDA approval per federal law so long as certain requirements are met by the compounder.

It applies to 503A compounders. The policy names state-licensed pharmacies, and licensed physicians. It does not name outsourcing facilities operating under section 503B. Smaller 503A pharmacies may have limited capacity, so supply may be constrained at first.

It does not cover research-use-only products. Peptides sold online as “for research use only” are outside this policy. Those products are not made for human use, and they are not prepared under pharmacy compounding standards. “Research use only” peptide ingredients cannot be used for compounding peptides under this policy.

It does not name doses or approved uses. The policy does not set doses, strengths, or indications. Those decisions remain with the prescriber.

What does the evidence say about these peptides?

The policy is a regulatory decision about enforcement. It is not an FDA evidence review and it is not an approval.

HHS’s stated rationale is that new lot-specific testing data from FDA-registered manufacturers answered many of the quality concerns FDA’s Center for Drug Evaluation and Research raised earlier. HHS also points to documented historical use. The testing and conditions address product quality. They do not establish that these peptides work for any condition.

For most of these peptides, the published research is mainly laboratory and animal work. That is why a prescribing clinician’s individual evaluation matters, and why patients should expect a candid conversation about what is and is not known.

What are supporters and critics saying?

Reactions have split along familiar lines.

Supporters say the policy creates a more controlled alternative to the gray market. HHS stated that it expects the policy to discourage widespread use of research-use-only peptides from foreign manufacturers. The chair of the American Academy of Peptide Medicine called it a landmark regulatory milestone.

Critics say the policy lets pharmacies dispense compounds without full FDA review. Consumer advocacy and public health groups, including Public Citizen and the Center for Science in the Public Interest, have raised safety concerns. The Partnership for Safe Medicines filed a citizen petition asking FDA to disregard the Advisory Committee’s recommendation.

Both views are part of the public record, and the situation is still developing.

What happens next?

Several milestones are ahead:

• Federal Register publication and comment period. Publication is scheduled for October 30, 2026, followed by a two-week public comment period on Docket No. HHS-OASH-2026-0496.
• FDA rulemaking. A final rule would decide whether each peptide goes on the 503A Bulks List. No date has been announced.
• State responses. State pharmacy and medicine boards may issue their own guidance.
• Additional peptides. The Advisory Committee is expected to review five more peptides by the end of February 2027.
• Possible policy changes. HHS says it may revise or withdraw the policy if safety signals or quality problems appear.

How can patients protect themselves?

If you are considering any peptide therapy, these steps lower risk.

1. Work with a licensed clinician. A patient-specific prescription is a requirement of the policy.
2. Ask where the medication is compounded. Use a state-licensed U.S. pharmacy that can describe its sourcing and testing.
3. Avoid research-use-only products. Research peptide powders are not made for human use and typically lack measured impurities thresholds, and sterility and endotoxin testing expected of compounded injectables.
4. Report problems. Tell your clinician right away about side effects, and ask how to report concerns to FDA’s MedWatch program.

For more on how pharmacy-compounded peptides differ from research chemicals, read Why All Peptides Are Not Created Equal.

How is Evergreen responding to this policy?

Evergreen Telehealth is LegitScript certified and reviews every clinical offering against clinical, pharmacy-quality, and state-law standards. We are reviewing the policy and its conditions. Any change to our treatment offerings will be posted on our treatments page after clinical, quality, and compliance review.

Medical review

Medically reviewed by Dr. Casey Greene, PharmD, IFMCP, Peptide Subject Matter Expert at Evergreen Telehealth. Last reviewed: November 10, 2026.

This article is for general education. It is not medical advice and does not replace an evaluation by a licensed clinician.

Frequently asked questions

Did the FDA approve BPC-157 and the other five peptides?

No. HHS states that the policy does not approve any of the six peptides or any compounded product made from them. The policy describes enforcement priorities while FDA continues rulemaking.

Can I buy these peptides online now?

Products sold online as “research use only” are outside the policy. They are not intended for human use and are not prepared under pharmacy compounding standards. The policy applies only to compounding by licensed pharmacies and physicians for individual patients with a prescription.

Can any pharmacy compound these peptides?

Only a state-licensed 503A pharmacy, federal facility, or licensed physician that meets every condition in the policy falls within it. Many pharmacies will need time to qualify their suppliers and testing. Supply may be limited at first.

Will my state allow these peptides?

That depends on your state. State boards of pharmacy and medicine set their own rules, and some states may be stricter than the federal policy. A licensed clinician can tell you what applies where you live.

Is Evergreen offering these peptides?

We are reviewing the policy. Any new treatment will be announced on our treatments page after clinical, pharmacy, and compliance review.

Sources

• U.S. Department of Health and Human Services. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, including Appendices A and B.
• Federal Register notice of availability, FR Doc. 2026-22192; Docket No. HHS-OASH-2026-0496; scheduled for publication October 30, 2026.
• Reuters. “US health department to allow temporary sale of some unapproved peptides.” October 28, 2026.
• NPR. “Small compounding pharmacies won’t be penalized for making peptides.” October 28, 2026.
• NBC News. “RFK Jr. takes shortcut to make some unapproved peptides available for use.” October 2026.
• The FDA Law Blog. “The PEPTIDE-L Wave Reaches HHS: Enforcement Discretion, Not the Finish Line.” October 28, 2026.
• Frier Levitt. “HHS Peptide Compounding Enforcement Discretion Policy.” October 2026.
• Lexology. “HHS Issues Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances.” October 2026.